Current Opinion in Oncology最新文献

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-05-01 Epub Date: 2025-04-03 DOI: 10.1097/CCO.0000000000001140

引用次数: 0

The role of biomarkers in the management of HPV-related oropharyngeal cancer. 生物标志物在hpv相关口咽癌治疗中的作用

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-05-01 Epub Date: 2025-02-05 DOI: 10.1097/CCO.0000000000001126

Benjamin D Hopkins, James E Bates

{"title":"The role of biomarkers in the management of HPV-related oropharyngeal cancer.","authors":"Benjamin D Hopkins, James E Bates","doi":"10.1097/CCO.0000000000001126","DOIUrl":"10.1097/CCO.0000000000001126","url":null,"abstract":"Purpose of review: Patients with HPV-related oropharyngeal cancer have very good survival outcomes but a high burden of toxicity. This has led to significant efforts to attempt to use a variety of biomarkers to select patients who are candidates for de-escalated treatment.Recent findings: Initially, the field used HPV status alone as a biomarker to select patients with oropharyngeal cancer for de-escalation, however, the recently presented results of NRG Oncology HN005 showed that this is an insufficient strategy to select patients for potential de-escalation as patients in that study who received 60 Gy rather than the standard 70 Gy of radiation had diminished progression-free survival. This has led to a myriad of other strategies to potentially identify patients who may be able to receive less intense treatment but maintain a high rate of cure.Summary: Many biomarker options exist to try and select patients for potential treatment de-escalation. We anxiously await the results of multiple ongoing phase II studies regarding many of these biomarkers and believe that the future of treatment for oropharyngeal cancer will be significantly more personalized.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"203-208"},"PeriodicalIF":2.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143536775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of PSMA PET/CT in imaging and management of prostate cancer. PSMA PET/CT在前列腺癌成像和治疗中的作用。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-05-01 Epub Date: 2025-02-13 DOI: 10.1097/CCO.0000000000001131

Nadine El Hoyek, Xiaolei Shi, Jason Jenkins, Wengen Chen

{"title":"Role of PSMA PET/CT in imaging and management of prostate cancer.","authors":"Nadine El Hoyek, Xiaolei Shi, Jason Jenkins, Wengen Chen","doi":"10.1097/CCO.0000000000001131","DOIUrl":"10.1097/CCO.0000000000001131","url":null,"abstract":"Purpose of review: In the era of precision medicine, the introduction of FDA-approved prostate-specific membrane antigen (PSMA) targeting tracers has revolutionized prostate cancer imaging. These tracers enable functional positron emission tomography (PET) imaging, allowing for precise identification of the location and extent of prostate cancer spread. This review serves as a practical guide for multidisciplinary teams caring for prostate cancer patients, outlining the current approved uses of PET imaging with PSMA tracers and exploring its future applications.Recent findings: PSMA PET/CT has become a reliable modality for initial staging in patients with intermediate-to-high risk prostate cancer, restaging in cases of biochemical recurrence and further clarifying disease status among patients with conventional imaging based nonmetastatic castrate resistant prostate cancer and metastatic prostate cancer. Additionally, it has promising roles in selecting patients for radioligand therapy, monitoring treatment response, and guiding therapeutic decision-making.Summary: PSMA PET/CT is currently a crucial imaging tool used at key stages of prostate cancer management, with ongoing research exploring its potential for additional clinical applications.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"233-239"},"PeriodicalIF":2.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metabolic landscape in bladder cancer. 膀胱癌的代谢景观。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-05-01 Epub Date: 2025-03-11 DOI: 10.1097/CCO.0000000000001137

Syrus Razavi, Amir Khan, De-Xue Fu, Dirk Mayer, David McConkey, Nagireddy Putluri, M Minhaj Siddiqui

{"title":"Metabolic landscape in bladder cancer.","authors":"Syrus Razavi, Amir Khan, De-Xue Fu, Dirk Mayer, David McConkey, Nagireddy Putluri, M Minhaj Siddiqui","doi":"10.1097/CCO.0000000000001137","DOIUrl":"10.1097/CCO.0000000000001137","url":null,"abstract":"Purpose of review: This review examines the existing literature on metabolic pathways associated with bladder cancer (BC) and investigates four domains: (1) diagnoses, (2) cancer classification (staging & grading), (3) tracking, and (4) treatment.Recent findings: A systematic search of relevant databases identified studies meeting predefined inclusion criteria. A diverse array of metabolic pathways was found to hold significant biological and clinical relevance to BC, with particular emphasis on amino acid (AA), lipid, nucleic acid (NA), and bioenergetic pathways. Recent studies have elucidated utilities for metabolomics in diagnosis of BC, staging and grading the disease, monitoring progression or recurrence, and informing treatment strategies. Specifically, fatty acids were observed to be upregulated by as much as 90-fold in studies focused on BC diagnosis, alongside the upregulation of AA metabolites. Metabolites such as AA, lipids, and aldehydes showed potential as diagnostic biomarkers for BC. NA metabolites were particularly effective in monitoring BC status postsurgical resection. Furthermore, metabolites from lipid, bioenergetic, and AA pathways demonstrated utility in predicting tumor cell sensitivity to chemotherapy.Summary: A broad spectrum of metabolic pathways and metabolites offers significant potential for applications in the diagnosis, staging, monitoring, and treatment of BC. These findings underscore the promise of metabolomics as a valuable tool in improving BC management and patient outcomes.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"259-266"},"PeriodicalIF":2.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genomic and transcriptomic sequencing in prostate cancer. 前列腺癌的基因组和转录组测序。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-05-01 Epub Date: 2025-02-27 DOI: 10.1097/CCO.0000000000001136

Safiullah Rifai, Azimullah Rifai, Xiaolei Shi, Mohammad Afnan Khan, Wei Guang, Linbo Wang, Luke Tallon, Arif Hussain

{"title":"Genomic and transcriptomic sequencing in prostate cancer.","authors":"Safiullah Rifai, Azimullah Rifai, Xiaolei Shi, Mohammad Afnan Khan, Wei Guang, Linbo Wang, Luke Tallon, Arif Hussain","doi":"10.1097/CCO.0000000000001136","DOIUrl":"10.1097/CCO.0000000000001136","url":null,"abstract":"Purpose of review: Genomic and transcriptomic sequencing technologies have revolutionized our ability to characterize prostate cancer at the molecular level. The underlying premise of next-generation sequencing technologies and their current and evolving applications in prostate cancer management are provided in the review.Recent findings: Improved methodologies are allowing timely sequencing of the coding regions or both the coding and noncoding regions of the genome to help identify potential mutations and structural variations in the prostate cancer genome, some of which are currently also targetable therapeutically. DNA microarray- based differential gene expression has been supplanted by RNA sequencing (RNA-seq), which not only allows for more accurate quantitation but also nucleotide-level resolution to investigate the entire transcriptome, including alternative gene spliced transcripts and noncoding RNA transcripts, whose full clinical implications have yet to be fully understood and realized. Gene classifier platforms that predict risk of recurrence or metastasis are being incorporated into prostate cancer management algorithms. In the appropriate clinical context, not only somatic but also germline mutation testing is being recommended.Summary: Continued clinical integration of sequencing technologies and ongoing research will lead to improved understanding of prostate cancer biology and prostate cancer treatment.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"240-249"},"PeriodicalIF":2.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Highlights of recent research focused on the treatment of advanced prostate cancer. 晚期前列腺癌治疗的最新研究亮点。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-05-01 Epub Date: 2025-03-19 DOI: 10.1097/CCO.0000000000001128

Theodore Gourdin

引用次数: 0

Polyamine metabolism in prostate cancer. 前列腺癌中的多胺代谢。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-05-01 Epub Date: 2025-02-20 DOI: 10.1097/CCO.0000000000001134

Laura A Sena

引用次数: 0

New trends in supportive care of head and neck cancers. 头颈癌支持性护理的新趋势。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-05-01 Epub Date: 2025-02-21 DOI: 10.1097/CCO.0000000000001135

Ilaria Mascagni, Paolo Bossi

{"title":"New trends in supportive care of head and neck cancers.","authors":"Ilaria Mascagni, Paolo Bossi","doi":"10.1097/CCO.0000000000001135","DOIUrl":"10.1097/CCO.0000000000001135","url":null,"abstract":"Purpose of review: Supportive care plays a vital role in the management of head and neck cancer (HNC) patients, as the disease often affects a frail and older population that is treated with multiple strategies and is associated with severe symptoms. We will focus on mucositis, dermatitis, dysphagia, pain, cachexia, and infections, as they are among the most common and challenging symptoms encountered.Recent findings: Efforts have focused on multiomics approaches to decipher the complex biological pathways that drive symptom onset and treatment-related toxicities, with the aim of developing novel therapeutic strategies. A notable example is ponsegromab, a monoclonal antibody designed to target cancer cachexia. Other promising areas of research, such as machine-learning models and the role of oral and gut microbiota on cachexia and mucositis, are actively being explored; however, their impact to date remains limited.Summary: In recent years, new knowledge has emerged regarding the underlying causes and predictive models for the supportive care of HNC patients. Unfortunately, this expanding body of knowledge primarily adds to complexity without translating into practical applications or substantial improvements for patients. Future efforts should prioritize the standardization of therapeutic algorithms, and the generation of robust evidence based on existing preclinical models.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"194-202"},"PeriodicalIF":2.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antibody-drug conjugates in rare genitourinary tumors: review and perspectives. 罕见泌尿生殖系统肿瘤中的抗体-药物偶联物：综述与展望。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-05-01 Epub Date: 2025-03-19 DOI: 10.1097/CCO.0000000000001141

Andre R Kydd, Md Shahid Sarwar, Saad Atiq, Raju Chelluri, Sandeep Gurram, Elias Chandran, Nicholas Simon, Ian Stukes, Sally Weng, Abbas Yousefi-Rad, A Rouf Banday, Salah Boudjadi, Andrea B Apolo

{"title":"Antibody-drug conjugates in rare genitourinary tumors: review and perspectives.","authors":"Andre R Kydd, Md Shahid Sarwar, Saad Atiq, Raju Chelluri, Sandeep Gurram, Elias Chandran, Nicholas Simon, Ian Stukes, Sally Weng, Abbas Yousefi-Rad, A Rouf Banday, Salah Boudjadi, Andrea B Apolo","doi":"10.1097/CCO.0000000000001141","DOIUrl":"10.1097/CCO.0000000000001141","url":null,"abstract":"Purpose of review: Rare cancers of the genitourinary (GU) tract are often clinically aggressive yet have few or no standard-of-care treatments. Multiple antibody-drug conjugates (ADCs) have been approved in solid malignancies. This review explores the use of ADCs in rare GU tumors in the context of biological pathways and ongoing research in solid tumors.Recent findings: Few clinical trials of ADCs focus on recruiting participants with rare tumors of the GU tract, including trials testing enfortumab vedotin as monotherapy or combined with pembrolizumab, and sacituzumab govitecan as monotherapy or combined with atezolizumab. We highlight many ongoing trials of novel ADCs for advanced/metastatic solid tumors and emphasize the potential eligibility of patients with rare GU tumors for tumor-agnostic trials.Summary: ADCs are being tested in multiple solid tumors, including rare GU tumors. Ongoing preclinical research supports the use of some ADCs in several rare GU tumors and improves our understanding of their pathophysiology.","PeriodicalId":10893,"journal":{"name":"Current Opinion in Oncology","volume":" ","pages":"250-258"},"PeriodicalIF":2.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970986/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel immunotherapy combinations in head and neck squamous cell carcinoma. 头颈部鳞状细胞癌的新型免疫治疗组合。

IF 2.8 4区医学

Current Opinion in Oncology Pub Date : 2025-05-01 Epub Date: 2025-02-07 DOI: 10.1097/CCO.0000000000001127

Shyam Kankotia, Soyun Park, Jacob Thomas

引用次数: 0